New research clarifies how neurotransmitters like norepinephrine, serotonin, and dopamine, are regulated - a finding that may help fine-tune therapies for depression.
Current drugs for depression target the regulatory process for neurotransmitters, and while effective in some cases, do not appear to work in other cases.
Recent findings suggest that synucleins, a family of small proteins in the brain, are key players in the management of neurotransmitters - specifically, alpha- and gamma-synuclein. Additionally, researchers have found elevated levels of gamma-synuclein in the brains of both depressed animals and humans.
In a study presented at the 39th annual meeting of the Society for Neuroscience, Georgetown University Medical Center researchers observed increased depressive-like behavior in mice where gamma-synuclein acts alone to regulate neurotransmitters, confirming earlier studies by this group.
"These findings show the importance of, and clarify a functional role for, gamma synuclein in depression and may provide new therapeutic targets in treatment of this disease," says Adam Oaks, a student researcher in the Laboratory of Molecular Neurochemistry at GUMC. "Understanding how current therapies work with the synucleins is important because the drugs don't work for all patients, and some are associated with side effects including an increased risk of suicide."
The study was funded by grants from the National Institutes of Health. A provision patent application has been filed by Georgetown University related to the technology described in this paper, on which Anita Sidhu, one of the authors, is an inventor.
However, some symptoms of depression, such as sleep and appetite disturbances, significant concentration problems, and chronic fatigue, interfere with your ability to make the life changes necessary to eliminate the depression. In more serious depression, suicidal thoughts and urges, and preoccupation with death, may require medication in addition to psychotherapy. Antidepressant medication can help relieve those symptoms, and allow you to make needed life changes. The decision to take medication, in addition to participating in psychological treatment, should be discussed with your treating psychologist and your primary care physician. - 30535
Current drugs for depression target the regulatory process for neurotransmitters, and while effective in some cases, do not appear to work in other cases.
Recent findings suggest that synucleins, a family of small proteins in the brain, are key players in the management of neurotransmitters - specifically, alpha- and gamma-synuclein. Additionally, researchers have found elevated levels of gamma-synuclein in the brains of both depressed animals and humans.
In a study presented at the 39th annual meeting of the Society for Neuroscience, Georgetown University Medical Center researchers observed increased depressive-like behavior in mice where gamma-synuclein acts alone to regulate neurotransmitters, confirming earlier studies by this group.
"These findings show the importance of, and clarify a functional role for, gamma synuclein in depression and may provide new therapeutic targets in treatment of this disease," says Adam Oaks, a student researcher in the Laboratory of Molecular Neurochemistry at GUMC. "Understanding how current therapies work with the synucleins is important because the drugs don't work for all patients, and some are associated with side effects including an increased risk of suicide."
The study was funded by grants from the National Institutes of Health. A provision patent application has been filed by Georgetown University related to the technology described in this paper, on which Anita Sidhu, one of the authors, is an inventor.
However, some symptoms of depression, such as sleep and appetite disturbances, significant concentration problems, and chronic fatigue, interfere with your ability to make the life changes necessary to eliminate the depression. In more serious depression, suicidal thoughts and urges, and preoccupation with death, may require medication in addition to psychotherapy. Antidepressant medication can help relieve those symptoms, and allow you to make needed life changes. The decision to take medication, in addition to participating in psychological treatment, should be discussed with your treating psychologist and your primary care physician. - 30535
About the Author:
Carlo Mueres is a experienced depression therapist who have been working with depression for seven years. If you want more his help please check his depression and anxiety guide!
